Droplet Digital PCR Patents: Who Leads, Where the Gaps Are 2026
Droplet Digital PCR Patents: Filing Trends, Leading Assignees and Open Claim Space
Filing peaked in 2019 at 336 records, then eased to 199 by 2024 — a 33% pullback over that three-year span, not a collapse of interest. Filings ran from 184 in 2017 to a peak of 336 in 2019, then declined to 199 by 2024 — a 33% drop across that three-year window. 2025 and 2026 figures are still incomplete because of publication lag and should not be read as a further decline.
- 1RGT UNIV OF CALIFORNIA8.6%
- 2BIO RAD LABORATORIES INC6.0%
- 3PROQR THERAPEUTICS II BV3.0%
- 4JUNO THERAPEUTICS INC2.5%
- 5YOUHEALTH ONCOTECH LTD2.0%
See the full droplet digital pcr analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about ddPCR patents
Who holds the most droplet digital PCR patents?
One assignee leads the ranked field with 225 families, well ahead of the fifth-place holder at 52. However, the top 5 assignees combined account for only 22.1% of the 2,628 records in scope, so no single company controls the field outright. The remaining filings are spread across a long tail of 90-plus other ranked assignees and unranked entrants, which means competitive monitoring needs to look beyond the top few names.
Is droplet digital PCR patent filing still growing?
Filing peaked in 2019 at 336 records and had fallen to 199 by 2024, a 33% decline over that three-year span. That decline should be read carefully: publication typically lags filing by about 18 months, so 2025 and 2026 figures in any dataset are still incomplete and cannot yet be read as continued decline. The honest read is that filing has normalised from an early peak, not that interest has disappeared.
What parts of ddPCR technology are least covered by existing patents?
Bioinformatics classified under G16B appears in only 5.4% of the 2,628 records, and lab apparatus under B01L in 7.5%, compared with 61.8% for core assay chemistry under C12Q. That gap suggests readout algorithms, rain-artifact classification, and low-cost partitioning hardware carry lighter claim density than the underlying chemistry, making them more realistic areas for a new first filing.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Droplet Digital PCR covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.